1. Cancer Institute NSW. All cancers data NSW. Sydney: Cancer Institute NSW, 2018. Available at https:// (accessed 14 April 2020).
  2. Whiteman DC, Webb PM, Green AC, Neale RE, Fritschi L, Bain CJ, et al. Cancers in Australia in 2010 attributable to modifiable factors: summary and conclusions. Aust NZ J Public Health 2010 Oct;39(5),477–84 doi: 10.1111/1753- 6405.12471. 
  3. Canberra: National Health and Medical Research Council (NHMRC). Australian guidelines to reduce health risks from drinking alcohol. [Internet] Available at: https://www.nhmrc. (accessed 08 April 2019). 
  4. Tracey EA, Roder DM, Currow DC. What factors affect the odds of NSW cancer patients presenting with localised cancer, as opposed to more advanced cancers? Cancer Causes Control 2012 Feb;23(2):255–62. 
  5. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšic M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD–3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018 Mar 17;391(10125):1023–1075 doi: 10.1016/S0140- 6736(17)33326-3. 
  6. 2016 preliminary population data are sourced from SAPHaRI (Center for Epidemiology and Evidence, NSW Ministry of Health (latest available data)). 
  7. LGA boundaries are based on the 2016 edition of the Australian Statistical Geography Standard produced by the Australian Bureau of Statistics. 
  8. Skipworth R, Parks R, Stephens N, et al. The relationship between hospital volume and post-operative mortality rates for upper gastrointestinal cancer resections: Scotland 1982–2003. Eur J Surg Oncol. 2010;36(2):141–7. 
  9. Annual NSW cancer incidence and mortality data set, 2015 (sourced from the NSW Cancer Registry, Cancer Institute NSW). 
  10. Begg S, Vos T, Barker B, Stevenson C, Stanley L and Lopez A. The burden of disease and injury in Australia 2003. PHE 82. Canberra: Australian Institute for Health and Welfare, 2007. Available at: table-of-contents (accessed 12 February 2020). 
  11. Centre for Epidemiology and Evidence. Health Statistics New South Wales. Sydney: NSW Ministry of Health. Available at: (accessed 12 February 2020). 
  12. Shihadeh, A, Azar S, Antonios C, Haddad A. Towards a topographical model of narghile water-pipe cafe smoking: a pilot study in a high socioeconomic status neighborhood of Beirut, Lebanon. Pharmacol. Biochem. Behav. 2004, 79(1):75-82. 
  13. Biffi R, Botteri E, Cenciarelli S, et al. Impact on survival of the number of lymph nodes removed in patients with node-negative gastric cancer submitted to extended lymph node dissection. Eur J Surg Oncol. 2011;37(4):305–11. 
  14. Naffouje SA and Salti, GI. Extensive lymph node dissection improves survival among American patients with gastric adenocarcinoma treated surgically: Analysis of the national cancer database. J Gast Cancer. 2017;17(4):319–30. 
  15. Okines A, Verheij M, Allum W, et al. Group EGW. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl_5):v50– v4. 
  16. National Academies of Sciences, Engineering, and Medicine. Public health consequences of e-cigarettes. Washington, DC: The National Academies Press 2018. doi: (accessed 14 February 2020). 
  17. Byrne S, Brindal E, Williams G, Anastasiou KM, Tonkin A, Battams S Riley MD (2018), E-cigarettes, smoking and health. A literature review update. Canberra: CSIRO. Available at: pdf.pdf (accessed 14 February 2020). 
  18. United States Department of Health and Human Services. The health consequences of smoking — 50 years of progress: a report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centres for Disease Control and Prevention, National Centre for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014. Available at: https://www.ncbi. pdf (accessed February 2020). 
  19. Parsons A, Daley A, Burgh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010 Jan 21;340:b5569 doi: 10.1136/bmj. b5569. 
  20. NSW Ministry of Health, Centre for Population Health. NSW Health Tobacco Strategy Work Plan 2019–2021. Available at: (accessed 3 February 2020). 
  21. Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann Boyce J, Lancaster T. Physician advice for smoking cessation. Cochrane Database of System Rev 2013 (5). Art. No.: CD000165 doi: 10.1002/14651858. CD000165.pub4. 
  22. International Agency for Research on Cancer. Estimated number of new cases in 2018, melanoma of skin, both sexes, all ages [Internet]. Global Cancer Observatory, Cancer Today 2018 [20 June 2019]. Available at: https://gco. (accessed 14 February 2020). 
  23. Australian Institute of Health and Welfare. Skin Cancer in Australia. Cat. No. CAN 96. Canberra: AIHW, 2016. 
  24. Whiteman DC, Webb PM, Green AC, Neale RE, Fritschi L, Bain CJ, et al. Cancers in Australia in 2010 attributable to modifiable factors: summary and conclusions. Aust NZ J Public Health 2010 Oct;39(5),477–84 doi: 10.1111/1753- 6405.12471. 
  25. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project. Diet, Nutrition, Physical Activity and the Prevention of Cancer. Summary of evidence. Available at (accessed 14 February 2019). 
  26. Cancer Australia. Position Statement 2015. Lifestyle risk factors and the primary prevention of cancer. - https:// prevention_of_cancer.pdf (accessed 14 February 2020). 
  27. National Health and Medical Research Council (NHMRC). Draft Australian Guidelines to Reduce Health Risks from Drinking Alcohol December 2019. Available at: https:// (accessed 14 February 2020) 
  28. Data sources, calculations and notes for Cancer in NSW data and the Cancer Statistics NSW module. Annual NSW cancer incidence and mortality data set, 2015 (sourced from the NSW Cancer Registry, Cancer Institute NSW). Available at: (accessed 14 February 2020). 
  29. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001 Oct 27;358 (9291):1389–99. 
  30. Breast Cancer Statistics, BreastScreen NSW, Sydney. Available at: (accessed 14 February 2020). 
  31. Australian Government Department of Health and Ageing. Evaluation of the BreastScreen Australia Program — Evaluation Final Report (pages 49–50). Screening Monograph No.1/2009. Canberra: Department of Health and Ageing, June 2009. 
  32. Fry, R. HRT makes mammograms less effective. ABC Science Online. Friday 12 January 2001. Available at: http:// htm?site=science/Askanexpert&topic=latest (accessed 14 February 2020). 
  33. Mousa, DS, Mello-Thoms, C, Ryan, EA, et al. Mammographic density and cancer detection: Does digital imaging challenge our current understanding? Acad Radiol, 2014. 21(11): 1377–1385. 
  34. McCormack, VA and I dos Santos Silva. Breast density, parenchymal patterns as markers of breast cancer risk: a meta-analysis, 2006. Cancer Epidemiol Biomarkers Prev, 15(6): 1159–69. 
  35. Pettersson, A, et al. Mammographic density phenotypes and risk of breast cancer: a meta-analysis, 2014. J Natl. Cancer Inst 2014 106(5): dju078. 
  36. Australian Institute of Health and Welfare. Cervical Screening in Australia 2013–14. Cancer Series no.97 Cat no. CAN 95. Canberra: AIHW, 2016. Available at: getmedia/c5e7776b-907e-4467-b435-8d6863ef33e7/19750. pdf.aspx?inline=true (Accessed 14 February 2020). 
  37. Cancer Council Australia. Introduction — Cervical cancer screening. Sydney: Cancer Council Australia, 2017. Available at cancer/Screening/Introduction (accessed on 9 April 2020). 
  38. World Health Organisation. Human Papillomavirus (HPV) Factsheets. WHO, 2010. Available at immunization/topics/hpv/en/ (accessed 19 May 2015). 
  39. Cancer Institute NSW. Cervical Screening in New South Wales. Annual statistical report 2012–2013. Sydney: Cancer Institute NSW, 2015. 
  40. Department of Health. Human papillomavirus (HPV) immunisation service. Canberra: Department of Health, 2018. Available at human-papillomavirus-hpv-immunisation-service (accessed 6 June 2019). 
  41. Ministry of Health. Additional Commonwealth and NSW-funded free vaccines. North Sydney: Ministry of Health, 2018. Available at: au/immunisation/ Pages/gp_catchup.aspx (accessed 6 June 2019). 
  42. Cancer Institute NSW: Bowel Cancer Statistics. Available at: (accessed 9 April 2020). 
  43. Cancer Institute NSW. NSW Cancer Plan: A statewide plan for lessening the impact of cancers in NSW. Sydney: Cancer Institute NSW, 2016. Available at: https://www.cancer.nsw. (accessed 14 February 2020). 
  44. Cancer Council Australia. Clinical practice guidelines for the prevention, early detection and management of colorectal cancer. Sydney: Cancer Council Australia, 2018. Available at cancer (accessed 14 February 2020). 
  45. O’Connell JB, Maggard MA and Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004.96(19): 1420–5. 
  46. Ananda SS, McLaughlin SJ, Chen F, Hayes IP, Hunter AA, Skinner IJ, et al. Initial impact of Australia’s National Bowel Cancer Screening Program. Med J Aust 2009;191(7):378– 381. 
  47. Australian Institute of Health and Welfare. National bowel cancer screening program: monitoring report 2019. Available at: 9b42-f68bfae112d2/aihw-can-125.pdf.aspx?inline=true. (Accessed 14 February 2020). 
  48. Oken MM, Creech RH, Tormey DC, Hortom J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982 Dec;5(6):649–55. 
  49. Bruera E, Kuehn N, Miller MJ, Selmer P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991 Summer;7(2):6–9.
  50. Wolf MS, Chang CH, Davis T, Makoul G. Development and validation of the Communication and Attitudinal Self-Efficacy scale for cancer (CASE-cancer). Patient Educ Couns 2005 Jun;57(3):333–41.
  51. Cancer Institute NSW. Prostate cancer statistics. Sydney: Cancer Institute NSW, 2018. Available from (accessed September 2019).
  52. Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10 year follow-up results of two randomised controlled trials. Lancet Oncol 2013 Oct;14(11):1086–1094. doi: 10.1016/S0140-6736(08)60348-7.
  53. Spooner D, Stocken DD, Jordan S, Bathers S, Dunn JA, Jevons C, et al. A randomised controlled trial to evaluate both the role and the optimal fractionation of radiotherapy in the conservative management of early breast cancer. Clin Oncol (R Coll Radiol) 2012 Dec;24(10):697–706. doi: 10.1016/j.clon.2012.08.003.
  54. Bane AL, Whelan TJ, Pond GR, Parpia S, Gohla G, Fyles AW, et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast-conserving therapy. Ann Oncol 2014 May;25(5):992–8. doi: 10.1093/annonc/mdu090.
  55. Price P, Hoskin PJ, Easton D, Austin D, Palmer SG, Yarnold JR. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 1986 Aug;6(4):247–55.
  56. Sze WM, Shelley M, Held I, Mason M. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy — a systematic review of the randomised trials. Cochrane Database Syst Rev 2004;(2):CD004721.
  57. Currow DC, You H, Aranda S, McCaughan BC, Morrell S, Baker DF, et al. What factors are predictive of surgical resection and survival from localised non-small cell lung cancer? Med J Aust. 2014 Oct 14;201(8):475–480.
  58. Coupland VH, Lagergren J, Lüchtenborg M, Jack RH, Allum W, Holmberg L, et al. Hospital volume, proportion resected and mortality from oesophageal and gastric cancer: a population-based study in England, 2004–2008. Gut 2013 Jul;62(7):961–6. doi: 10.1136/gutjnl-2012-303008.
  59. Riaz, SP, Lüchtenborg M, Jack RH, Coupland VH, Peake MD, Møller H. Variation in surgical resection for lung cancer in relation to survival: population-based study in England 2004–2006. Eur J Cancer 2012 Jan;48(1):54–60. doi: 10.1016/j.ejca.2011.07.012.
  60. Koppert LB, Lemmens VE, Coebergh JW, Steyerberg EW, Wijnhoven BP, Tilanus HW, et al. Impact of age and co-morbidity on surgical resection rate and survival in patients with oesophageal and gastric cancer. Br J Surg 2012 Dec; 99(12):1693–700. doi: 10.1002/bjs.8952.
  61. Creighton N, Walton R, Roder DM, Aranda S, Richardson AJ, Merrett N, et al. Pancreatectomy is underused in NSW regions with low institutional surgical volumes: a population data linkage study. Med J Aust. 2017;206(1):23–29.
  62. Chang GJ, Rodriguez-Bigas MA, Skibber JM, et al. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007 Mar 21;99(6):433–414.
  63. Wong, SL. Lymph node counts and survival rates after resection for colon and rectal cancer. Gastrointest Cancer Res 2009 Mar–Apr;3(2 Suppl 1):S33–S35.
  64. Compton CC, Fielding PL, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000 Jul;124(7):979–942.
  65. Rouvelas I, Lagergren J. The impact of volume on outcomes after oesophageal cancer surgery. ANZ J Surg 2010;80(9):634–41.
  66. Smith RC, Creighton N, Lord RV, Merrett ND, Keogh GW, Liauw WS, et al. Survival, mortality and morbidity outcomes after oesophagogastric cancer surgery in New South Wales, 2001–2008. Med J Aust 2014;21;200(7):408–13.
  67. Eskander A, Merdad M, Irish JC, Hall SF, Groome PA, Freeman JL, et al. Volume-outcome associations in head and neck cancer treatment: a systematic review and meta-analysis. Head & Neck 2014;36(12):1820-34. doi: 10.1002/hed.23498.
  68. David JM, Ho AS, Luu M, Yoshida EJ, Kim S, Mita AC, et al. Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer. Cancer. 2017;123(20):3933–42. doi: 10.1002/cncr.30843.
  69. Boaz A, Hanney S, Jones T, Soper B. Does the engagement of clinicians and organisations in research improve healthcare performance: a three-stage review. BMJ Open 2015;5(12):e009415. doi:10.1136/ bmjopen-2015–009415. 
  70. Ozdemir BA, Karthikesalingam A, Sinha S, Poloniecki JD, Hinchliffe RJ, Thompson MM, et al. Research activity and the association with mortality. PLoS One 2015; 10(2):e0118253. doi:10.1371/journal.pone.0118253.
  71. Clarke M, Loudon K. Effects on patients of their healthcare practitioner’s or institution’s participation in clinical trials: a systematic review. Trials 2011 Jan 20;12(16).
  72. Downing A, Morris EJ, Corrigan N, Sebag-Montefiore D, Finan PJ, Thomas JD, et al. High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. Gut 2017 Jan;66(1):89–96. doi: 10.1136/gutjnl-2015-311308.